Prestige Consumer Healthcare Inc. quarterly report, Q1 FY2015

Business context and reporting period

This is Prestige Brands Holdings, Inc.’s Form 10-Q for the three months ended June 30, 2014 (first quarter of fiscal 2015; fiscal year ends March 31). The filing describes a marketer and distributor of over-the-counter healthcare and household cleaning products. The supplied request identifies Prestige Consumer Healthcare, but the filing itself names Prestige Brands Holdings, Inc.

Beginning this quarter, the company reported three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning. Prior-year segment information was reclassified for comparison.

Financial results and key metrics

• Cost of sales rose 7.3% to $63.8 million, faster than revenue, reducing gross margin. Management attributed pressure to product and customer mix, including increased lower-priced dollar-channel sales, partly offset by acquired international brands.
• General and administrative expense increased to $17.0 million from $11.6 million, primarily reflecting $4.2 million of acquisition costs, higher stock-based compensation, and increased professional costs.
• Interest expense declined to $14.7 million from $15.9 million. The effective tax rate increased to 40.6% from 38.3%, mainly due to acquisition-related nondeductible items.
• Cash and cash equivalents were $15.7 million at June 30, down from $28.3 million at March 31. Current assets were $160.1 million and current liabilities $78.3 million.
• Capital spending was $0.5 million. Investing cash outflow of $78.5 million primarily reflected the $78.0 million Hydralyte acquisition. Financing provided $36.1 million, including $35.0 million of net revolver borrowings.
• Debt principal was $972.5 million, up from $937.5 million at March 31; net of cash, debt was approximately $956.8 million. The company reported $60.0 million of remaining ABL revolver capacity and compliance with debt covenants.

Material changes versus the prior comparable period

• Total revenue growth was driven by International OTC Healthcare, up $10.3 million largely from Care Pharma and Hydralyte, and Household Cleaning, up 7.7%. North American OTC Healthcare revenue fell 7.3% to $110.4 million.
• North American declines included analgesics, dermatologicals, and gastrointestinal products. Management cited prior-year product-launch comparisons, consumer shifts and private-label competition for Beano, and timing effects and supply issues affecting Gaviscon.
• Contribution margin fell 2.4% to $62.8 million. North American contribution margin declined 10.8%, partly offset by improvement in International OTC Healthcare.
• Operating cash flow increased despite lower net income, which management attributed primarily to working-capital movements and higher noncash charges.
• The company completed the Hydralyte brand acquisition on April 30 for $78.0 million, recording $73.6 million of preliminary non-amortizable intangible assets and $1.2 million of goodwill.

Outlook, commentary, risks and unusual items

• The company had agreed to acquire Insight Pharmaceuticals for $750.0 million in cash; the transaction had not closed as of the filing. Management anticipated closing in fiscal 2015’s second quarter, subject to customary conditions, including antitrust clearance. Financing was expected from cash, the revolver, and an amendment to the term loan. The company expected to divest one Insight gastrointestinal brand in connection with regulatory approval.
• Management estimated an effective tax rate of approximately 36.0% for the remaining fiscal 2015 quarters, excluding acquisition impacts and discrete items. The filing gives no broader quantified earnings or revenue guidance.
• Key risks include high leverage, variable interest rates, competition and pricing pressure, customer concentration, reliance on third-party manufacturers, acquisition execution and integration, and potential impairment of goodwill and intangible assets. Goodwill and intangible assets totaled $1.66 billion; no impairment was recorded this quarter.
• Walmart represented approximately 19.2% of gross sales and 22.4% of accounts receivable at quarter-end. Five brands accounted for approximately 42.0% of revenue.
• Variable-rate debt included $287.5 million under the term loan and $35.0 million under the revolver. Management estimated that a 1 percentage-point rate increase would adversely affect pretax earnings and cash flow by approximately $2.5 million for the quarter.
• Routine legal matters were not expected by management to have a material adverse effect, taking reserves into account. The filing notes that actual outcomes can differ from estimates. Disclosure controls were assessed as effective, with no material change in internal control reported.

Important facts for investors to verify

1. Whether the Insight acquisition closed on schedule, its final financing terms, regulatory conditions, and any required brand divestiture.
2. Whether North American OTC sales and margins stabilized, particularly in analgesics, dermatologicals, and gastrointestinal products.
3. Hydralyte’s and Care Pharma’s contribution to growth and profitability, and whether Hydralyte’s preliminary purchase-price allocation changed.
4. Debt levels, revolver availability, covenant headroom, interest-rate exposure, and liquidity following the Insight transaction.
5. Customer concentration and exposure to Walmart, as well as reliance on third-party manufacturers and distribution infrastructure.
6. Assumptions supporting the substantial goodwill and intangible-asset balances, given brand declines and impairment sensitivity.